Altimmune (ALT)
(Delayed Data from NSDQ)
$7.51 USD
+0.49 (6.98%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.52 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALT 7.51 +0.49(6.98%)
Will ALT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALT
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Other News for ALT
Goldman Sachs raises obesity drug market estimate to $130B
A Better Way To Crash The GLP-1 Party
Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024